Clinical Trials in Prato, Tuscany
2 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled293 locationsNCT06926868
Recruiting
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
Metastatic Breast CancerHER2-negative Breast CancerER Positive Breast Cancer
Fondazione Sandro Pitigliani150 enrolled1 locationNCT04660435